The steady-state level of nucleophosmin/B23 mRNA decreased during berberine-induced (25 microg/ml, 24 to 96 hr) apoptosis of human leukemia HL-60 cells. A decline in telomerase activity was also observed in HL-60 cells treated with berberine. A stable clone of nucleophosmin/B23 overexpressed in HL-6
Arecoline-induced death of human leukemia K562 cells is associated with surface up-modulation of TNFR2
✍ Scribed by Ying-Jung Chen; Long-Sen Chang
- Publisher
- John Wiley and Sons
- Year
- 2012
- Tongue
- English
- Weight
- 936 KB
- Volume
- 227
- Category
- Article
- ISSN
- 0021-9541
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
The goal of the present study is to explore the contribution of tumor necrosis factor‐α (TNFα)‐related pathway to the cytotoxicity of arecoline on human leukemia K562 cells. Arecoline treatment induced death of K562 cells and increased surface expression of TNFα, TNFR1, and TNFR2. Unlike that of TNFR1 mRNA, transcriptional levels of TNFα and TNFR2 mRNA increased in arecoline‐treated cells. Moreover, arecoline‐induced down‐regulation of ADAM17 maturation was involved in surface up‐modulation of TNFR1, TNFR2, and TNFα. Arecoline‐elicited increase in intracellular Ca^2+^ concentration was responsible for JNK/c‐Jun pathway activation and ERK inactivation. Abolition of JNK/c‐Jun pathway suppressed arecoline‐induced increase in transcriptional level of TNFα and TNFR2 mRNA. TNFα and TNFR2 promoter luciferase activity and chromatin immunoprecipitating analyses revealed that c‐Jun increasingly bound with TNFα and TNFR2 promoter upon arecoline treatment. Over‐expression of constitutively active MEK1 abolished the effect of arecoline on suppressing ADAM17 maturation. Pretreatment with TNFR2 antibody abrogated arecoline‐induced increased susceptibility of K562 cells for the cytotoxicity of TNFα and arecoline‐induced cell death. Taken together, our data suggest that up‐modulation of TNFR2 surface expression is associated with arecoline‐induced death of K562 cells. J. Cell. Physiol. 227: 2240–2251, 2012. © 2011 Wiley Periodicals, Inc.
📜 SIMILAR VOLUMES
## Abstract The anti‐neoplastic effects of 1,25‐dihydroxyvitamin D~3~ (1,25D) are well documented in numerous tumor cell systems and animal models of cancer. However, despite this pre‐clinical success, the clinical use of 1,25D is currently impeded by the dose‐limiting hypercalcemia, and the risk o